Of note, PD-L1 expression on tumor cells has been shown to correlate with poor prognosis in patients with RCC (Fig. 2) 34, MEL, and breast, pancreatic, stomach, bladder, lung, liver, and ovarian cancers (Table 2) 33,35–38. This evidence concerns the gene CD274 and neoplasm.